Compare SOLS & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | SNN |
|---|---|---|
| Founded | 2025 | 1856 |
| Country | United States | United Kingdom |
| Employees | 4400 | 16988 |
| Industry | Aerospace | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 14.3B |
| IPO Year | N/A | N/A |
| Metric | SOLS | SNN |
|---|---|---|
| Price | $76.60 | $30.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $79.25 | $36.25 |
| AVG Volume (30 Days) | ★ 1.7M | 943.6K |
| Earning Date | 05-06-2026 | 03-16-2026 |
| Dividend Yield | 0.38% | ★ 2.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.36 | $8.58 |
| Revenue Next Year | $5.64 | $5.60 |
| P/E Ratio | ★ $54.31 | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.43 | $28.02 |
| 52 Week High | $84.44 | $38.79 |
| Indicator | SOLS | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 32.56 |
| Support Level | $70.72 | N/A |
| Resistance Level | $83.53 | $33.89 |
| Average True Range (ATR) | 2.93 | 0.61 |
| MACD | -0.55 | -0.28 |
| Stochastic Oscillator | 7.15 | 0.69 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.